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INTRODUCTION
Atherosclerotic heart disease usually manifests as angina
and is diagnosed by stress imaging tests and coronary
angiography (1), but some patients with typical angina and
documented myocardial ischemia have normal coronary
arteries (2), a clinical picture called cardiac syndrome X (3).
Endothelial (4) and microvascular (5) dysfunction have been
suggested to play a pathogenic role in this situation. Patients
with slow coronary flow (SCF) (6) and endothelial dysfunc-
tion (7) are both at increased risk for cardiovascular events.
Several methods to measure endothelial injury can provide
clinical opportunities to identify these patients (8), but the
evaluation of endothelial function in arterial and venous
vascular beds has not yet been performed. The aim of this
study was to evaluate the arterial and venous endothelial
functions in patients with stable angina and normal
coronary anatomy but SCF on a cardiac angiogram.
MATERIALS AND METHODS
This case-control study was previously approved by the
institutional ethics committee and involved 21 patients
referred for coronary angiography to evaluate coronary
artery disease. The inclusion criteria were angina, a myo-
cardial perfusion defect (stress imaging test) and normal
coronaries (coronary angiography). The exclusion criteria
were myocardial infarction in the last 60 days, heart
transplantation, a revascularization procedure, left ventricu-
lar dysfunction, systemic inflammatory diseases, autoim-
mune diseases, obesity, smoking, hematological disorders,
hemodialysis and the current use of anticoagulant, corticos-
teroid or immunosuppressive therapy.
The patients underwent elective coronary angiography
using the standard Judkins technique (9). The coronary
arteries were visualized in the left and right oblique planes
using cranial and caudal angles. Left ventriculography was
performed in the right anterior oblique view. The injection
of contrast medium was recorded at a speed of 30 frames/s.
Coronary flow was quantified objectively by two indepen-
dent observers, who were blinded to the clinical character-
istics of the participants. The TIMI frame count was assessed
as described in the literature, and the longer left anterior
descending artery frame counts were corrected by dividing
by 1.7 to derive the corrected TIMI frame count (CTFC). The
patients with a CTFC greater than two standard deviations
from the normal published range for the particular vessel
were accepted as having SCF (10). The average TIMI frame
count for each subject was calculated by adding the TIMI
frame counts for the left anterior descending artery, left
circumflex artery, and right coronary artery and then
dividing the value obtained by three.
The participants had their blood collected in the fasting
state to measure glycemia, total cholesterol, high-density
lipoprotein cholesterol (HDL-c), triglycerides (automated
enzymatic commercial kits; Roche, Mannheim, Germany),
insulin (enzyme immunoassay commercial kits; Abbot-
Murex, Park, IL, USA), and C-reactive protein (nephelome-
try, nephelometer BN100, Dade Behring Inc., Marburg,
Germany). Low-density lipoprotein cholesterol (LDL-c) was
calculated using the Friedewald formula. The homeostasis
model assessment of insulin resistance (HOMA-IR) was
calculated as previously described (11). The patients were
instructed not to use medications for 72 h before the
endothelial evaluations.
Venous endothelial function was evaluated by the dorsal
hand vein technique (12,13). A 23-gauge butterfly needle was
inserted into a vein on the back of the hand. A continuous
infusion (Harvard infusion pump, South Natick, MA) of
saline solution (rate, 0.3 mL/min) was started. A tripod
holding a linear variable differential transformer (model
025 MHR; Shaevitz Engineering, Pennsauken, NJ) was
mounted on the hand to measure the diameter of the vein.
The readings were taken at a congestive pressure of
40 mmHg by the inflation of a blood pressure cuff placed
on the upper portion of the arm under study. The diameter of
the vein during the saline infusion with the cuff inflated was
defined as 100% relaxation. The vein was preconstricted by
infusing increasing doses (7 min each) of phenylephrine (37-
25000 ng/mL) until the dose that produced approximately
70% constriction (ED70%) of the vein was identified; this dose
was used as a reference for the subsequent experiments. The
vasodilation produced by six doses (12-12000 ng/mL) of
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677acetylcholine (endothelium-dependent) andthree doses (156-
3125 ng/mL) of sodium nitroprusside (endothelium-inde-
pendent) was analyzed (3 min each). The individual effects
were analyzed as the percentage of maximum venodilation
(13).
Flow-mediated vasodilation (FMD) was measured to
evaluate the arterial endothelium-dependent vasodilation
using a high-resolution vascular ultrasound (EnVisor CHD;
Philips, Bothell, WA, USA) and a 3-12 MHz linear-array
transducer (L12-3, Philips, Bothell, WA, USA). Briefly, the
change in the brachial artery diameter after 60 s of reactive
hyperemia was compared with a baseline measurement
after the deflation of a cuff that had been placed around the
forearm and inflated to 50 mmHg above the systolic blood
pressure for 5 min (14). The diameter increase after a
sublingual nitroglycerin spray (0.4 mg) was used as a
measurement of endothelium-independent vasodilation.
The vessel diameter responses to reactive hyperemia and
to nitroglycerin were expressed as the percentage changes
relative to the diameter immediately before cuff inflation
and to the diameter immediately before drug administra-
tion.
The data are presented as the means¡SD. The distribu-
tions of the variables were determined using Shapiro–Wilk
tests of normality. GraphPad Software Prism 4.0 was used
for comparisons with ANOVA (using the Bonferroni post hoc
test), Fisher’s exact test, the Mann-Whitney test and the
unpaired t test, as appropriate, and for Pearson correlations.
A 5% level of significance was set for all tests performed.
RESULTS
Of the 21 patients enrolled in our study, nine (cases) were
considered to be patients with SCF, and 12 (controls) had
normal coronary flow; their characteristics are presented in
Table 1. The SCF group had a higher body mass index,
triglycerides, glycemia and HOMA-IR and lower HDL-c
compared with the control group. Metabolic syndrome was
more common in the SCF group. The usage patterns of
aspirin, statins, angiotensin converting enzyme inhibitors,
calcium channel blockers and beta-blockers were similar
between the groups.
The CTFC was higher in the patients with SCF than in the
controlsforeachmajorepicardialcoronaryartery:leftanterior
descending artery (36¡3 vs. 47.3¡24), left circumflex artery
(22¡4 vs. 31.4¡6), and right coronary artery (20¡3 vs.
34.9¡11). In addition, the average TIMI frame count was
higher in the patients with SCF than in the controls (26¡4 vs.
37.9¡12).
Endothelium-dependent venodilation, measured as the
maximum venodilation by acetylcholine, was 40% lower in
the SCF group (Table 2). Venoconstriction induced by
phenylephrine and venodilation induced by sodium nitro-
prusside (endothelium-independent venodilation) were
similar between the groups. The dose of phenylephrine
needed to reach ED70% and the doses of acetylcholine and
sodium nitroprusside needed to reach maximum venodila-
tion were similar between the groups. Endothelial arterial
function assessed by FMD was 45% lower in the SCF group
(p=0.022). Nitroglycerin-induced vasodilation was similar
between the groups. Brachial artery flow-mediated vasodi-
lation was inversely correlated with the C-reactive protein
level (r=-0.668; p=0.049).
DISCUSSION
Here, we show that patients with SCF, normal coronary
arteries and documented myocardial ischemia display
arterial and venous endothelial dysfunction, which was
not observed in similar patients with normal coronary flow.
In addition, we show that venous endothelial dysfunction is
observed in patients with SCF and normal coronary arteries.
Multiple abnormalities have been reported to explain
cardiac syndrome X, including endothelial dysfunction (15),
increased oxidative stress (16) and vascular inflammation
(17). The observation that SCF has also been associated with
metabolic abnormalities (18) and endothelial dysfunction
(19) may link these abnormalities. Previous studies showed
arterial endothelial dysfunction in patients with SCF
(15,17,20). One of these studies reported that CTFC
correlates with endothelial function, even in individuals
with normal coronary flow (15). However, both the arterial
and venous endothelium can be injured in patients with
cardiovascular risk factors (21,22), and their treatment can
reverse the endothelial dysfunction in both vascular beds
(22), which could occur in patients with SCF. Under
physiological conditions, the venous endothelium is sub-
jected to a lower shear stress and O2 concentration compared
with the arterial endothelium (23), but arterial vasodilation
is reduced when the venous endothelium is injured (24),
Table 1 - Baseline clinical and laboratory characteristics of the study subjects.
Parameters
Controls
(n=12)
Slow Coronary Flow
(n=9) p-value
Gender (F/M) 4/8 3/6 0.999
Age (years) 52.2¡10 58.0¡10 0.230
Body mass index (kg/m
2) 25.4¡3 29.9¡5 0.044
Systolic blood pressure (mmHg) 122.8¡10 133.3¡18 0.116
Diastolic blood pressure (mmHg) 78.1¡9 82.2¡9 0.343
Hemoglobin (g/dL) 13.8¡1 14.7¡1 0.608
C-reactive protein (mg/dL) 0.29¡0.2 0.48¡0.3 0.145
Total cholesterol (mg/dL) 198.7¡36 183.2¡55 0.475
Triglycerides (mg/dL) 88.9¡26 131.1¡52 0.047
LDL-c (mg/dL) 121.4¡30 113.5¡54 0.703
HDL-c (mg/dL) 59.5¡14 43.4¡8 0.006
Fasting plasma glucose (mg/dL) 86.6¡8 99.2¡10 0.019
Insulin (mU/mL) 5.4¡3 10.3¡6 0.051
HOMA-IR 2.1¡1 4.7¡3 0.045
Data are shown as the means¡SD. HOMA-IR=homeostasis model assessment of insulin resistance.
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678suggesting that substances produced by the venous
endothelium can influence arteriolar tonus (24,25). Thus,
venous endothelium dysfunction can contribute to the
microvascular spasm observed in patients with SCF.
Endothelial dysfunction and increased reactive oxygen
species may trigger the production of cytokines and cell
adhesion molecules (26). Patients with SCF present
decreased plasma concentrations of adiponectin (27) and
increased serum levels of soluble adhesion molecules
(ICAM-1, VCAM-1 and E-selectin) (19) and C-reactive
protein (28). Our data revealed that C-reactive protein was
associated with arterial endothelial dysfunction, suggesting
additional repercussions of systemic inflammation in the
arterial bed.
Lipid profile changes, insulin resistance and the fre-
quency of metabolic syndrome were more frequent in
patients with SCF and endothelial dysfunction, as demon-
strated in the literature (19,29), suggesting a common
ground for these alterations (18).
Our study has several limitations: the sample size was
small, it was a single-center study and only patients with
stable conditions were selected. The observational nature of
the study does not allow cause and effect relationships to be
determined. Nonetheless, the completeness of the evaluations
is a strength that can provide new insights into this puzzling
issue that should be tested and validated in larger studies.
In conclusion, patients with SCF and normal coronary
arteries present venous and arterial endothelial dysfunction,
suggesting that this condition might be a systemic vascular
phenomenon.
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